Lilly to Supply COVID Antibody Therapies

Indianapolis-based Eli Lilly and Co. (NYSE: LLY) and the Bill & Melinda
Gates Foundation in Seattle have formed an agreement to provide access to
COVID-19 therapeutic antibodies for low- and middle-income countries. Lilly
says the agreement is part of the COVID-19 Therapeutics Accelerator
initiative to reduce the burden of the virus on healthcare systems
worldwide.

Lilly says the accelerator is an initiative launched by the Gates
Foundation, as well as London-based Wellcome, and Mastercard (NYSE: MA) to
speed the development of and access to therapies for COVID-19.

“Medicines that can help reduce the impact of COVID-19 will be an important
part of the solution to this pandemic and are urgently needed by people all
over the world,” said David Ricks, Lilly’s chairman and chief executive
officer. “Lilly is proud to be a part of the collective global effort to
help ensure equitable access to COVID-19 therapeutic options for people in
low- and middle-income countries.”

Source: Inside Indiana Business with Gerry Dick

Photo courtesy of Bill & Melinda Gates Foundation